C-erbB-2 overexpression and survival in early onset breast cancer.
about
Being 40 or younger is an independent risk factor for relapse in operable breast cancer patients: the Saudi Arabia experienceExpression of the apoptosis-related genes BCL-2 and BAD in human breast carcinoma and their associated relationship with chemosensitivity.Age-specific gene expression signatures for breast tumors and cross-species conserved potential cancer progression markers in young womenBCL-2 family protein, BAD is down-regulated in breast cancer and inhibits cell invasionEffect of postmastectomy radiotherapy in patients <35 years old with stage II-III breast cancer treated with doxorubicin-based neoadjuvant chemotherapy and mastectomy.HER2/neu Immunostaining in Invasive Breast Cancer: Analysis of False Positive Factors.Frequent loss of the BLID gene in early-onset breast cancer.gef gene expression in MCF-7 breast cancer cells is associated with a better prognosis and induction of apoptosis by p53-mediated signaling pathwayTargeted therapy in breast cancer: the HER-2/neu gene and protein.Serum HER-2 concentration in patients with primary breast cancer.Amplification of the HER2 gene in breast cancers testing 2+ weak positive by HercepTest immunohistochemistry: false-positive or false-negative immunohistochemistry?Tumour biomarker expression relative to age and molecular subtypes of invasive breast cancer.The Predictive Value of Serum HER2/neu for Response to Anthracycline-Based and Trastuzumab-Based Neoadjuvant Chemotherapy.Differential expression of prognostic biomarkers between interval and screen-detected breast cancers: does age or family history matter?Breast cancer subtypes and survival in chinese women with operable primary breast cancer.PD-1 rs2227982 Polymorphism Is Associated With the Decreased Risk of Breast Cancer in Northwest Chinese Women: A Hospital-Based Observational Study.Tumor aromatase expression as a prognostic factor for local control in young breast cancer patients after breast-conserving treatment.Signalling between microvascular endothelium and cardiomyocytes through neuregulin.Cholesterol biosynthesis inhibitors as potent novel anti-cancer agents: suppression of hormone-dependent breast cancer by the oxidosqualene cyclase inhibitor RO 48-8071.Ten-year survival in women with primary stage IV breast cancer.
P2860
Q33308326-6B70156D-2973-4F57-B828-3BC18982EC8EQ34075056-FDD7BB36-FE3F-4C0D-B98B-B94AB0386518Q34737360-D7ED5881-C872-44F1-A242-B6CA3CF7950CQ35006788-B8033594-B032-4E52-AC70-7711100391ECQ35087264-D86A1338-2C8D-4984-B41F-6C03BC53391AQ35323892-13B2E66B-EA9D-4400-9991-356E3DE53977Q35545663-95D84E4B-1A6F-4CF3-9C5E-FF16EA5CEE3FQ35600102-FBED29CD-92F5-497D-BFA7-F3E1C1CE1E7CQ35648508-C0A057DE-83F1-481F-96EB-7CA11215DA64Q35769870-53D41C6B-2F76-4AFB-B960-689CCBCDD99BQ35954388-BA32E012-B910-4DE3-BB20-E3ADBCA58E51Q36089922-381A6170-AAE3-4BC3-9B4F-E2C81F15FF2FQ36092023-118A209C-6E2F-45F3-9086-46B9E3E15BC7Q36361958-BCF07D80-6B5F-49DD-9783-C823C3333EE9Q36654658-459862DE-3484-4DBC-920B-7E53F671D787Q36992949-C82D1246-899D-46D1-B837-04D1EA7D64D6Q37360208-492886FD-8A7D-4A4F-B195-1B62AA4AA868Q37707158-612387B9-975D-4219-BCB1-ED893159C94BQ38989942-F094884D-EB9E-41B1-A321-5203ED198624Q40581747-A5B21B5B-5FB9-40D7-A9FD-93DE66100117
P2860
C-erbB-2 overexpression and survival in early onset breast cancer.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
C-erbB-2 overexpression and survival in early onset breast cancer.
@en
C-erbB-2 overexpression and survival in early onset breast cancer.
@nl
type
label
C-erbB-2 overexpression and survival in early onset breast cancer.
@en
C-erbB-2 overexpression and survival in early onset breast cancer.
@nl
prefLabel
C-erbB-2 overexpression and survival in early onset breast cancer.
@en
C-erbB-2 overexpression and survival in early onset breast cancer.
@nl
P2093
P2860
P356
P1476
C-erbB-2 overexpression and survival in early onset breast cancer.
@en
P2093
P2860
P2888
P356
10.1023/A:1006498721508
P407
P577
2000-09-01T00:00:00Z
P6179
1019162700